Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.
The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.
An awaited update on early data for a CAR-NK therapeutic shows disappointing efficacy and duration, but a different chemotherapy conditioning regimen for lymphodepletion is showing early promise in acute myeloid leukemia.
Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.
- In Vitro Diagnostics
- Medical Devices
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Diagnostic Equipment & Supplies
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Ahon Pharmaceutical Co., Ltd.
- Fosun Kite Biotechnology Co., Ltd.
- Fosun Pharma Kite Biotechnology Co. Ltd.
- Guilin Pharma
- Jiangsu Wanbang Biopharmaceutical Group Co., Ltd.
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Shenyang Hongqi Pharmaceuticals Co., Ltd.,
- Fosun Industrial Co., Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.